A 35-year-old woman from Mumbai with newly diagnosed classical Hodgkin lymphoma (mixed cellularity subtype) undergoes staging. CT chest shows a 7 cm anterior mediastinal mass with compression of the superior vena cava (SVC). Abdominal CT shows para-aortic lymphadenopathy. PET-CT confirms Stage IIIB disease. She has no B symptoms. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has intermediate-to-advanced stage cHL (Stage IIIB) with a bulky mediastinal mass causing SVC compression — a feature of unfavorable prognosis. The presence of bulky disease (≥7 cm) and advanced stage mandates intensified chemotherapy. ## Risk Stratification in cHL **Key Point:** Advanced-stage cHL with bulky disease (≥7 cm) or extranodal involvement is classified as **unfavorable/high-risk** and requires escalated chemotherapy (BEACOPP) rather than standard ABVD. **High-Yield:** Escalated BEACOPP (6–8 cycles) is superior to ABVD in advanced-stage cHL with unfavorable features, achieving 5-year PFS of ~85–90% vs. ~70–75% with ABVD alone. ### Rationale for Escalated BEACOPP 1. **Higher dose intensity** — BEACOPP delivers higher cumulative doses of alkylating agents and etoposide 2. **Superior efficacy in advanced disease** — HD21 trial and other prospective studies show BEACOPP advantage in Stage III–IV disease 3. **Bulky mediastinal mass** — requires aggressive systemic therapy; SVC compression is NOT an indication for immediate stenting before chemotherapy 4. **No B symptoms** — favorable prognostic factor within the unfavorable stage category ### Management of SVC Compression - **Chemotherapy-first approach** — BEACOPP is initiated; most bulky masses respond rapidly (within 1–2 cycles) - **SVC stent** — reserved for refractory/progressive SVC obstruction despite chemotherapy; not needed upfront - **Supportive care** — elevate head of bed, diuretics, consider low-dose corticosteroids if severe symptoms **Clinical Pearl:** Bulky mediastinal masses in cHL often show dramatic response to chemotherapy alone; invasive procedures (stenting, biopsy) should be deferred unless chemotherapy fails or complications develop. ## Why Not the Other Options? | Option | Why Incorrect | |--------|---------------| | Immediate SVC stent | SVC stenting is NOT first-line; chemotherapy is initiated first. Stenting is reserved for refractory obstruction or acute decompensation. | | Standard ABVD 4 cycles | ABVD is insufficient for advanced-stage unfavorable cHL. Escalated BEACOPP (6–8 cycles) is the standard of care for Stage III–IV disease. | | Mediastinal mass biopsy | Biopsy is unnecessary; diagnosis is already confirmed by lymph node biopsy. PMBL is a separate entity (CD20+, EBV−, lacks RS cells). No re-biopsy needed before treatment. | [cite:Harrison 21e Ch 104]